CERo Therapeutics Holdings, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing cell therapy product candidates. The company has not generated revenue and does not expect product sales in the foreseeable future, reflecting its pre-commercial stage. Its business model is centered on advancing preclinical and clinical programs toward regulatory approval, with any future revenue expected to come from product commercialization, licensing, milestones, or R&D services. Because it is still funding development and public-company operations, CERo currently depends on external financing rather than operating cash flow.
0.30
0.30
| % | |
|---|---|
| Cell therapy product candidates | 0% Experimental therapeutic candidates being advanced through preclinical and clinical development. |
| Research and development services | 0% Potential future R&D services and collaboration work tied to development programs. |
| Licensing and partnering rights | 0% Out-licensing of product candidates and related rights to third parties. |
| Milestones and royalties | 0% Contingent future payments tied to development, approval, or product sales outcomes. |
CERo does not currently sell commercial products, so it does not yet have a traditional customer base...
Equity investors and financing counterparties that fund the company while it develops product candidates and maintains listing compliance.
CROs, consultants, and other service providers that support preclinical work, clinical planning, and public-company administration.
Biopharma partners that could license product candidates or collaborate on development in exchange for upfront, milestone, or royalty payments.
Hospitals, physicians, and patients that would use approved therapies if the company successfully commercializes a product.
CERo is headquartered in the United States and its reported business activity is centered on U.S. capital markets, U.S...
CERo’s immediate strategic priority is to fund and advance its preclinical and clinical development programs toward...
The company has no revenue and needs financing to support ongoing research, clinical work, and operating overhead.
Regulatory progress is the main path to any future product revenue or partnering value.
Licensing or milestone-based collaborations could create non-product revenue before full commercialization.
The company’s largest risk is financing risk: it has no revenue, expects losses to continue, and states that current...
The company has no revenue and states that existing cash will not fund operations for 12 months, so it must raise capital to continue development.
The business depends on successful preclinical and clinical progress and eventual regulatory approval, which are inherently uncertain.
Recent financings included common stock, pre-funded warrants, preferred stock, and conversion features that can materially change ownership and earnings per share.
The company has had to manage stockholders’ equity thresholds and other listing requirements, which can affect market access and investor confidence.
CELU · Pharmaceutical Preparations
BCTX · Pharmaceutical Preparations
CVKD · Pharmaceutical Preparations
SPRO · Pharmaceutical Preparations
KAPA · Pharmaceutical Preparations
MCRB · Pharmaceutical Preparations
: 11/08/2026